NuCana (NCNA) Change in Intangibles (2017 - 2025)
NuCana's (NCNA) quarterly Change in Intangibles came in at -$66508.3 in Q4 2025, down 3.64% year-on-year from -$69017.6 in Q4 2024, and down 4.87% quarter-over-quarter from -$63420.0 in Q3 2025.
NuCana (NCNA) Change in Intangibles (2017 - 2025) Analysis & Trends
NuCana has disclosed Change in Intangibles across 9 years of filings, most recently posting -$66508.3 for Q4 2025.
- Change in Intangibles for Q4 2025 came in at -$66508.3, down 3.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$275959.3 (up 25.15% YoY), and the FY2025 annual result was -$254472.5, up 31.12% from the prior year.
- Change in Intangibles came in at -$66508.3 for Q4 2025 at NuCana, down from -$63420.0 in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of -$63420.0 in Q3 2025 to a low of -$625476.9 in Q4 2021.
- The 5-year median for Change in Intangibles is -$129458.1 (2022), against an average of -$176059.4.
- Peak annual rise in Change in Intangibles reached 62.7% in 2021, while the deepest fall reached 146.71% in 2021.
- NuCana's Change in Intangibles stood at -$625476.9 in 2021, then surged by 77.85% to -$138524.6 in 2022, then gained by 13.09% to -$120391.7 in 2023, then surged by 46.69% to -$64175.1 in 2024, then decreased by 3.64% to -$66508.3 in 2025.
- The last three Change in Intangibles figures came in at -$66508.3 (Q4 2025), -$63420.0 (Q3 2025), and -$64175.1 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Intangibless (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.96 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | -66,508.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66,508.31 |
| Dec 31, 2025 | -66,508.31 |
| Sep 30, 2025 | -63,420.02 |
| Sep 30, 2025 | -63,420.02 |
| Dec 31, 2024 | -64,175.09 |
| Dec 31, 2024 | -64,175.09 |
| Sep 30, 2024 | -81,855.91 |
| Sep 30, 2024 | -81,855.91 |
| Jun 30, 2024 | -119,910.97 |
| Jun 30, 2024 | -119,910.97 |
| Mar 31, 2024 | -102,749.97 |
| Mar 31, 2024 | -102,749.97 |
| Dec 31, 2023 | -120,391.73 |
| Dec 31, 2023 | -120,391.73 |
| Sep 30, 2023 | -108,934.89 |
| Sep 30, 2023 | -108,934.89 |
| Jun 30, 2023 | -165,179.94 |
| Jun 30, 2023 | -165,179.94 |
| Mar 31, 2023 | -193,266.01 |
| Mar 31, 2023 | -193,266.01 |